March 20, 2019
A regulatory change in 2016 didn't require the Centers for Medicare & Medicaid Services to retroactively reclassify STI Pharma LLC's antibiotic Sulfatrim as a "non-innovator" generic that carried a lower rebate rate for the drugmaker, the Department of Health and Human Services has told a federal court.